Recent

% | $
Quotes you view appear here for quick access.

Old Republic International Corporation Message Board

jagan1961 751 posts  |  Last Activity: 14 hours ago Member since: Oct 31, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    From the boardhost site by damartiinez

    by nvaa2 18 hours ago
    jagan1961 jagan1961 14 hours ago Flag

    No body cares whether you are going to buy or not. At the end of the day the Big boyz are the ones who moves this one way or the other. Not individuals like you and me.

    Who bought 20+ mln shares, many individuals would have dumped for few pennies or panicked at EOD and gave it at a loss.

    I see a 10-15 MLN short trade on Friday, with 41% insider holding, there is bound to be some buying interest to short covering and for a buyout prospect.

    I expect the share should move past 5 by Friday.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 14 hours ago Flag

    I'm saying Friday's PR with more negative emphasis.

    Sentiment: Strong Buy

  • jagan1961 jagan1961 14 hours ago Flag

    Probably it might be the insiders who orchestrated the new PR, to trap the shorts.

    Now if they have purchased all the shares on Friday, the shorts will be in a deep doo doo.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Moreover they shorted more today too from 2.95 to 2.75.

    Where are they going to get it, by next week it will be back to $6-7 range easy.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 16 hours ago Flag

    Almost 15 MLN shares shorted on Friday at the bottom.

    You will have to hang in tight for a week or so, I'm a firm believer here, there is going to be a takeover!

    With 6-7 $ right now anyone can scoop them up, it is worth the risk, even if they capture 10-20% of the market share which is almost 600 MLN $ sales.

    GL!

    Sentiment: Strong Buy

  • 95% of the trades were above $3 range and btw 3.10-3.20 range.

    Someone will buy them out, with 30 MLN shares o/s even @6-7 with 2 Ph 2 Drugs and 1 Ph 1 Drug & $1.75 per share cash, it is worth the risk for the buying entity.

    Just hang in tight folks.

    GLTA LONGS!
    ,

    Sentiment: Strong Buy

  • Reply to

    From the boardhost site by damartiinez

    by nvaa2 18 hours ago
    jagan1961 jagan1961 17 hours ago Flag

    At these low valuations, with no one entity holding a controlling a stake, a buyout is not ruled out and that too a quick one.

    GL!

    Sentiment: Strong Buy

  • Just watch here, 20-25 MLN shares at these bottom prices is very difficult to cover.

    Hold it till end of this week, you can sell for 5-6$ range. Look at today's action on Biotech Buyout/Mergers.
    GLTA LONGS!

    Sentiment: Strong Buy

  • With $1.75 in cash, 2 PH 2 Drugs and 1 Ph 1 this has the potential to move back up.

    The safety of Squalamine is established and it is orally applied, that is a Huge positive. Patients will try out the Oral medication before poking their eye, that is why this drug will be approved and will be the 1st line therapy for AMD, till another one comes out.

    I would expect a huge accumulation by the Funds today at these ultra low prices and the shorts needs to chase to cover their position.

    GL!

    Sentiment: Strong Buy

  • Reply to

    Tomorrow $$$$$$$$

    by yebin1649 Mar 29, 2015 6:55 PM
    jagan1961 jagan1961 Mar 29, 2015 9:32 PM Flag

    Generally the stock will not be available if you put a sell order 20-25% of the closing price, that is near to the current price.

    Moreover some of the aggressive brokerages might lend, however if the shares are sold they will immediately cover.

    When you have this much of sell off, there will be a follow-on selling, however since it went below $3 there won't be margin pressure sell off. It is only 25 Mln o/s and $1.75 cash available.

    The potential of this one popping up is Very high here. Moreover the results are not that bad to warrant a huge sell off like this.

    GL!

    Sentiment: Strong Buy

  • Reply to

    Why is There No Partner?

    by dhm3159 Mar 29, 2015 1:11 PM
    jagan1961 jagan1961 Mar 29, 2015 4:43 PM Flag

    "In patients with classic CNV (ITT-LOCF), mean gains in visual acuity were +10.5 letters for the OHR-102 combination arm and +5.4 letters with Lucentis monotherapy, a clinically meaningful benefit of +5.1 letters"

    On Fovista,

    "In this study, Fovista® 1.5mg administered in combination with Lucentis® (ranibizumab injection) demonstrated statistically significant superiority compared to Lucentis® monotherapy based on the primary endpoint of mean change in visual acuity from baseline at 24 weeks. Patients receiving the combination of 1.5 mg of Fovista® and Lucentis® gained a mean of 10.6 letters from baseline on a standardized chart of vision testing compared to a mean gain of 6.5 letters from baseline for patients receiving Lucentis® monotherapy, representing a 62% comparative benefit from baseline. Fovista® exhibited a favorable safety profile and no significant safety imbalances were observed for Fovista® combination therapy as compared to Lucentis® monotherapy."

    The biggest benefit of OHR-102 is oral administration of the Drug, which is 100 times better than multiple injections on the Eye, which is very expensive to administer and should be avoided whenever possible.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Mar 29, 2015 3:20 PM Flag

    The sell off was an orchestrated take down by the shorts. They just simply on a naked "SELL SELL MISSION" without realizing,

    The O/s equity is just 25+ Mln shares
    They have 40+ MLN in the bank to conclude the PH 3 trials ($1.75 per share)
    They have 2 Drug candidates in Ph 2 and 1 Drug candidate in PH 1
    All 3 Analysts who follow this company closely did not rate to sell, rather reduced the Target price

    The shorties, looked at the Yahoo old info, thought they have just 41 cents (10 MLN in cash) and started to sell and on top of it a Headline news too.

    They will have to chase this back up to cover. The price will move back to $6 before the end of next week, irrational selling.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Mar 29, 2015 10:30 AM Flag

    Agreed, they have 41 MLN in cash, 3 Drug candidates, 2 in PH2. Squalamine will get ph 3 approval, due to the way it is applied, even if this is slightly inferior to the injectible ones, even though it doesn't look like that way.

    These drugs are not easy to develop and get approval, that is why there is huge money involved. At these prices any one will scoop them up, the risk/reward favors the acquiring company big time.

    GLTA LONGS!

    Sentiment: Strong Buy

  • Reply to

    Beyond the knee jerk- OHRP

    by medchemlead Mar 28, 2015 11:47 AM
    jagan1961 jagan1961 Mar 28, 2015 10:45 PM Flag

    A non-injectible drug has a great advantage to patient population, even though its efficacy could be of lesser degree. They can work on it to make it much better, say for a specific set of patient population.

    If there is no efficacy and they won't be allowed to proceed for Ph 3 trials too. per their conf. call they will be proceeding with a Ph 3 trial. This is a very lucrative drug candidate, with the PPS being so low, anyone can buy them out @6-7 $ easy here.

    They have 40 + MLN which can sustain their operation till 2016.

    GL!

    Sentiment: Strong Buy

  • They have over 40+ mln $ and their expenses are 3-4 MLN $ per qtr. Do your math.

    The stock has 1.75$ cash per share and 2 PH 2 drugs and 1 PH 1 Drug.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Mar 28, 2015 1:03 PM Flag

    There is no need to call anyone names. No one is genius in this market place from Creamer to Najarains, everyone is #$%$ to the core. Everyone has a way of thinking, it looks you were right, you got credit whatever it deserves and made money if you were short.

    It looks like either the PR job was poor here, the Conf. call was not that bad and 3 analysts who were at the call, did not give a sell call.

    The stock will move back to 6-7 range and it is way oversold.

    GLTA LONGS!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Mar 28, 2015 12:54 PM Flag

    Even though I believe this will pass Phase III and will get FDA approval.

    This will be better than the 2 Injections per year, so long as this is a oral drug. I suspect with the way the stock is trading, anyone would like to buy them out for 150-200 MLN $ price range and work on it further.

    They have 2 Ph 2 drug and 1 on Ph 1.

    $6-7 range someone will scoop them up.

    GL!

    Sentiment: Strong Buy

  • jagan1961 jagan1961 Mar 28, 2015 11:01 AM Flag

    I listened to the conf. call they can enough money to go thru the PH 3.

    I'm of the view this is a perfect setup for a sale to a competitor or a big pharma.

    GL!

    Sentiment: Strong Buy

  • Currently the valuation is around 75 MLN, if anyone buys with a 100% premium you have 3 potential drug candidates.

    I doubt any big BIO will leave this opportunity behind. Even this SQUALAMINE will provide enough efficacy for a subgroup of the patient population.

    GL!

    Sentiment: Strong Buy

  • Now the cloud hanging over LL is cleared. The tests are the same as what LL is conducting. Both GS and Janney capital have upgraded the stock. The stock is trading at 1/3 prior to TIlson Scamsters actions.

    Watch for a nice bounce and new investors taking a decent position. Continued rise till it touches 50-60 level now.

    If you have some positions in IRA/ROTH then just don't trade, this stock will be 80-90 levels in 1 year.

    The Assets 330 Stores and a robust profitable business with Zero debt and low equity base of just 26 MLN shares, supports a Price of $100-125 range easy.

    GLTA LONGS!

    Sentiment: Strong Buy

ORI
14.97+0.27(+1.84%)Mar 30 4:02 PMEDT